120 related articles for article (PubMed ID: 14653433)
1. alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
Adeoye OM; Ferrell RE; Kirshner MA; Mulsant BH; Seligman K; Begley AE; Reynolds CF; Pollock BG
J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):235-9. PubMed ID: 14653433
[TBL] [Abstract][Full Text] [Related]
2. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients.
Laghrissi-Thode F; Pollock BG; Miller MC; Mulsant BH; Altieri L; Finkel MS
Psychopharmacol Bull; 1995; 31(4):659-63. PubMed ID: 8851637
[TBL] [Abstract][Full Text] [Related]
3. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods.
Houck PR; Mazumdar S; Koru-Sengul T; Tang G; Mulsant BH; Pollock BG; Reynolds CF
Psychiatry Res; 2004 Dec; 129(2):209-15. PubMed ID: 15590048
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial.
Kok RM; Nolen WA; Heeren TJ
Int J Geriatr Psychiatry; 2007 Dec; 22(12):1247-54. PubMed ID: 17562523
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
6. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
7. Orosomucoid influences the response to antidepressants in major depressive disorder.
Harley J; Roberts R; Joyce P; Mulder R; Luty S; Frampton C; Kennedy M
J Psychopharmacol; 2010 Apr; 24(4):531-5. PubMed ID: 19395425
[TBL] [Abstract][Full Text] [Related]
8. Residual cognitive impairment in late-life depression after a 12-month period follow-up.
Portella MJ; Marcos T; Rami L; Navarro V; Gastó C; Salamero M
Int J Geriatr Psychiatry; 2003 Jul; 18(7):571-6. PubMed ID: 12833300
[TBL] [Abstract][Full Text] [Related]
9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
11. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
13. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
Rosenberg C; Lauritzen L; Brix J; Jørgensen JB; Kofod P; Bayer LB
Psychopharmacol Bull; 2007; 40(1):63-73. PubMed ID: 17285097
[TBL] [Abstract][Full Text] [Related]
14. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression.
Janssen J; Hulshoff Pol HE; Schnack HG; Kok RM; Lampe IK; de Leeuw FE; Kahn RS; Heeren TJ
Int J Geriatr Psychiatry; 2007 May; 22(5):468-74. PubMed ID: 17357181
[TBL] [Abstract][Full Text] [Related]
15. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment.
Deuschle M; Sander P; Herpfer I; Fiebich BL; Heuser I; Lieb K
Psychiatry Res; 2005 Jul; 136(1):1-6. PubMed ID: 16024091
[TBL] [Abstract][Full Text] [Related]
16. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
17. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
Kishino S; Nomura A; Itoh S; Nakagawa T; Takekuma Y; Sugawara M; Furukawa H; Todo S; Miyazaki K
Eur J Clin Pharmacol; 2002 Dec; 58(9):621-8. PubMed ID: 12483455
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
19. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
Dobkin RD; Menza M; Bienfait KL; Gara M; Marin H; Mark MH; Dicke A; Tröster A
J Neuropsychiatry Clin Neurosci; 2010; 22(2):188-95. PubMed ID: 20463113
[TBL] [Abstract][Full Text] [Related]
20. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
